0%

est. 2Y upside i

Series A

Rank

#2244

Sector

Synthetic Biology

Est. Liquidity

~7Y

Data Quality

Data: Low

Insufficient data to assess equity upside.

Last updated: July 3, 2026

Bull (15%)0%

No quantifiable upside due to missing valuation and revenue data. Could benefit from AI-driven enzyme design demand.

Base (55%)0%

Unable to compute base case; lack of financials precludes meaningful projection.

Bear (30%)0%

High incumbent threat and early stage imply risk of failure; no revenue baseline.

Est. time to liquidity~7.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

$15M total funding implies a preference overhang; exact ratio depends on unknown valuation.

Dilution Risk

high

Early stage and capital intensity suggest significant future dilution before exit.

Secondary Liquidity

none

No secondary trading data available; likely illiquid until exit.

Questions to Ask at the Interview

Strategic questions based on Enzymit's data — designed to show you've done your homework.

  • 1

    “What is the company's current post-money valuation and revenue run rate?”

  • 2

    “How does Enzymit's AI enzyme design differ from open-source models like RFdiffusion?”

  • 3

    “What is the expected timeline to a liquidity event, and is there a secondary market for shares?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.